Bioxcel Therap | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 120 K

LB filings
2025.08.12 13:04
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 120 K, missing the estimate of USD 212.5 K.

EPS: As of FY2025 Q2, the actual value is USD -2.45, missing the estimate of USD -1.8575.

EBIT: As of FY2025 Q2, the actual value is USD -15.85 M.

Segment Revenue

  • Product Revenue, Net: $120 thousand for the three months ended June 30, 2025, compared to $1,104 thousand for the same period in 2024. For the six months ended June 30, 2025, product revenue was $288 thousand, compared to $1,686 thousand for the same period in 2024.

Operational Metrics

  • Cost of Goods Sold: $107 thousand for the three months ended June 30, 2025, compared to $62 thousand for the same period in 2024. For the six months ended June 30, 2025, cost of goods sold was $121 thousand, compared to $141 thousand for the same period in 2024.
  • Research and Development Expenses: $10,256 thousand for the three months ended June 30, 2025, compared to $8,032 thousand for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $14,810 thousand, compared to $19,433 thousand for the same period in 2024.
  • Selling, General and Administrative Expenses: $5,609 thousand for the three months ended June 30, 2025, compared to $9,450 thousand for the same period in 2024. For the six months ended June 30, 2025, selling, general and administrative expenses were $11,308 thousand, compared to $22,715 thousand for the same period in 2024.
  • Net Loss: $19,187 thousand for the three months ended June 30, 2025, compared to $8,299 thousand for the same period in 2024. For the six months ended June 30, 2025, net loss was $26,441 thousand, compared to $35,090 thousand for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: $24,618 thousand for the six months ended June 30, 2025, compared to $40,880 thousand for the same period in 2024.
  • Net Cash Provided by Financing Activities: $13,339 thousand for the six months ended June 30, 2025, compared to $31,930 thousand for the same period in 2024.

Unique Metrics

  • Inventory Write-Downs: $95 thousand for the three months ended June 30, 2025, compared to $0 for the same period in 2024. For the six months ended June 30, 2025, inventory write-downs were $95 thousand, compared to $45 thousand for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company is focusing on the commercialization of IGALMI® and the development of BXCL501 for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and Alzheimer’s disease. The company is also advancing its SERENITY At-Home pivotal Phase 3 trial and plans to generate additional Phase 3 efficacy and safety data in its TRANQUILITY In-Care trial.
  • Non-Core Business: The company has deprioritized the development of BXCL701 programs, except for certain ongoing trials, and is evaluating strategic options for its subsidiary, OnkosXcel Therapeutics.
  • Priority: The company is prioritizing the development and commercialization of BXCL501 and IGALMI® in the at-home setting and care facilities, with a focus on generating additional clinical data to support regulatory submissions and potential label expansions.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.